Efficacy of cefminox in the treatment of bacterial infections.
In an open trial, 1841 patients were treated with mainly 1 g of cefminox twice a day in adults or 20-30 mg/kg three or four times a day in children for up to 14 days. The clinical efficacy was assessed in 1560 patients (1256 adults, 304 children) and the efficacy rates were as follows: 82.3% in respiratory tract infections (n:525), 85.7% in biliary tract infections (n:87), 66.4% in urinary tract infections (n:509), 92.1% in gynaecological infections (n:126), 88.1% in peritonitis (n:84), 74.9% in all infections (n:1560). The overall bacterial response rates in single infections were 81.5% (81.5% for Staphylococcus aureus, 98.4% for Escherichia coli, 98.6% for Haemophilia influenzae and 38.8% for Pseudomonas aeruginosa). The safety of cefminox was assessed in 1831 patients. Adverse side-effects were reported in 35 patients (1.9%), the most frequent being rash.
Omoto
S
S
Pharmaceutical Division, Meiji Seika Kaisha, Tokyo, Japan.
Watanabe
S
S
D001424:Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology; D002513:Cephamycins / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D008297:Male; D012973:Sodium Hypochlorite; D014018:Tissue Distribution
D002513:Cephamycins; D012973:Sodium Hypochlorite; C046079:cefminox